2023 annual financial data
ArriVent BioPharma 2023 Operating margin
Direct answer
Operating margin was Not calculable.
Operating income was -74,590,000 USD and net income was -69,333,000 USD.
Operating cash flow was -55,842,000 USD.
Get free ArriVent BioPharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -74,590,000 USD
- Net income
- -69,333,000 USD
- Operating cash flow
- -55,842,000 USD